Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Trial of Leflunomide, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma

NCT04508790 is registered in ClinicalTrials.gov with City of Hope Medical Center as lead sponsor.

NCT NCT04508790
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04508790 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Trial of Leflunomide, Pomalidomide, and Dexamethasone for Relapsed/Refractory Multiple Myeloma
Lead sponsor
City of Hope Medical Center
Phase
Phase 2
Overall status
Recruiting
Start date
November 24, 2020
Completion date
February 14, 2027
Enrollment
29 (estimated)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent plasma cell myeloma, refractory plasma cell myeloma